drugset / Trial / NCT04388202
Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram
RandomizedParallel-groupOpen-labelTreatment
Summary
The LEAP-SE study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.
Timeline
- Start
- 2020-10-15
- Primary completion
- 2023-05-30
- Completion
- 2023-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Escitalopram | Small molecule | 10 mg | — |
| Comparator | Escitalopram | Small molecule | 20 mg | — |
| Subject | Sertraline | Small molecule | 100 mg | — |
| Subject | Sertraline | Small molecule | 200 mg | — |